Drugs / Anti-GPRC5D CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05749133 | Apr 2023 → Mar 2025 | plasma cell myeloma | XuYan | Unknown | No outcome recorded |
| Phase 1/2 | NCT05739188 | Feb 2023 → Feb 2025 | plasma cell myeloma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-GPRC5D CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05739188 ↗ |
| Modality | Cell therapy | “Anti-GPRC5D chimeric antigen receptor (CAR) modified T cells” NCT05739188 ↗ |
| Route | Intravenous | “receive intravenous infusion of anti--GPRC5D CAR-T Cells” NCT05739188 ↗ |
| Target | GPRC5D | “Anti-GPRC5D CAR-T” NCT05739188 ↗ |